Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema

Bowen, Tom; Cicardi, Marco; Bork, Konrad; Zuraw, Bruce L.; Frank, M.; Ritchie, Bruce; Farkas, Henriette; Varga, Lilian; Zingale, Lorenza C.; Binkley, Karen; Wagner, Éric; Adomaitis, Peggy; Brosz, Kristylea; Burnham, Jeanne; Warrington, Richard; Kalicinsky, Chrystyna; Mace, Sean R.; McCusker, Christine; Schellenberg, R. Robert; Celeste, Lucia; Hébert, Jacques; Valentine, Karen; Poon, Man‐Chiu; Serushago, Bazir; Neurath, Doris; Yang, William H.; Lacuesta, Gina; Issekutz, Andrew C.; Hamed, Azza; Kamra, Palinder; Dean, John Mark; Kanani, Amin; Stark, Donald; Rivard, Georges‐Étienne; Leith, Eric; Tsai, Ellie; Waserman, Susan; Keith, Paul K.; Page, David; Marchesin, Silvia; Longhurst, Hilary; Kreuz, W.; Rusicke, E.; Martinez‐Saguer, Inmaculada; Aygören‐Pürsün, Emel; Harmat, G.; Füst, George; Li, Henry; Bouillet, Laurence; Caballero, Teresa; Moldovan, Dumitru; Späth, Peter; Smith-Foltz, Sara; Nagy, István; Nielsen, Erik Waage; Bucher, Christoph; Nordenfelt, Patrik; Xiang, Zhi Yu

doi:10.1016/s1081-1206(10)60584-4

Cited by 178 publications

(340 citation statements)

References 62 publications

Supporting

Mentioning

325

Contrasting

Unclassified

Order By: Relevance

“…Patients with HAE are often misdiagnosed, resulting in unnecessary medical and surgical interventions[22,31,34]. Abdominal symptoms may mimic an acute appendicitis or other forms of acute abdomen and lead to unnecessary abdominal surgery[2,8,22]. According to 1 estimate, 45% of patients presenting to an emergency department with an HAE attack are subsequently hospitalized[35].…”

Section: Consequencesmentioning

confidence: 99%

“…C1-esterase inhibitor, attenuated androgens, antifibrinolytics, icatibant, and fresh frozen plasma have been used successfully for short-term prophylaxis[2,8,25,54]. Consensus guidelines recommend that patients with HAE receive prophylactic treatment with 500 to 1,500 U of C1-esterase inhibitor 1 to 6 hours before the procedure[25].…”

Section: Treatment Approachesmentioning

confidence: 99%

“…The antifibrinolytic agents, ε -aminocaproic acid and tranexamic acid, are not approved in the United States but have been used extensively in some European countries for long-term prophylaxis, especially in children and pregnant women in whom androgen therapy is contraindicated because of significant risk of adverse effects[4,8,37]. Antifibrinolytics may also be useful in other patients in whom attenuated androgens or intravenous therapy is not appropriate.…”

Section: Treatment Approachesmentioning

confidence: 99%

“…Side effects may include weight gain, acne, virilization, altered libido, menstrual irregularities, headaches, depression, fatigue, lipid abnormalities, hypertension, cholestasis, increased liver enzymes, peliosis hepatitis, and hepatocellular adenomas[2,8,59,69-73]. To review the published safety data on these agents, we performed a literature search and identified articles that included an evaluation of the safety of long-term attenuated androgen therapy in HAE (Table 2)[59-62,70,72-76].…”

Section: Experience With Attenuated Androgen Therapy In the Long-termmentioning

confidence: 99%

“…Studies based on national HAE registries show a minimal prevalence ranging from 1.09 to 1.51 in 100,000 inhabitants,[5-7] with the actual prevalence expected to be higher. Estimates indicate that approximately 1 in 50,000 people in the general population has HAE[8]. No sex or race predominance has been described[3].…”

mentioning

confidence: 99%

See 4 more Smart Citations

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

Gower¹,

Busse²,

Aygören‐Pürsün³

et al. 2011

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

Hereditary angioedema (HAE) caused by C1-esterase inhibitor deficiency is an autosomal-dominant disease resulting from a mutation in the C1-inhibitor gene. HAE is characterized by recurrent attacks of intense, massive, localized subcutaneous edema involving the extremities, genitalia, face, or trunk, or submucosal edema of upper airway or bowels. These symptoms may be disabling, have a dramatic impact on quality of life, and can be life-threatening when affecting the upper airways. Because the manifestations and severity of HAE are highly variable and unpredictable, patients need individualized care to reduce the burden of HAE on daily life. Although effective therapy for the treatment of HAE attacks has been available in many countries for more than 30 years, until recently, there were no agents approved in the United States to treat HAE acutely. Therefore, prophylactic therapy is an integral part of HAE treatment in the United States and for selected patients worldwide. Routine long-term prophylaxis with either attenuated androgens or C1-esterase inhibitor has been shown to reduce the frequency and severity of HAE attacks. Therapy with attenuated androgens, a mainstay of treatment in the past, has been marked by concern about potential adverse effects. C1-esterase inhibitor works directly on the complement and contact plasma cascades to reduce bradykinin release, which is the primary pathologic mechanism in HAE. Different approaches to long-term prophylactic therapy can be used to successfully manage HAE when tailored to meet the needs of the individual patient.

show abstract

Section: Consequencesmentioning

confidence: 99%

Section: Treatment Approachesmentioning

confidence: 99%

Section: Treatment Approachesmentioning

confidence: 99%

Section: Experience With Attenuated Androgen Therapy In the Long-termmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

Gower¹,

Busse²,

Aygören‐Pürsün³

et al. 2011

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Pharmacokinetics of single and repeat doses of icatibant

Leach

Spencer

Mascelli

et al. 2015

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

show abstract

Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System Database

2012

View full text Add to dashboard Cite

The extracted cases from the AERS indicate continuing reports of thrombotic events associated with the use of one C1 esterase inhibitor product among patients with hereditary angioedema. The AERS is incapable of establishing a causal link and detecting the true frequency of an adverse event associated with a drug; however, potential signals of C1 esterase inhibitor product-associated thrombotic events among patients with hereditary angioedema were identified in the extracted combination cases.

show abstract

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema

Cited by 178 publications

References 62 publications

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

Pharmacokinetics of single and repeat doses of icatibant

Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System Database

Contact Info

Product

Resources

About